Compounds > sarafloxacin hydrochloride
Page last updated: 2024-12-06

sarafloxacin hydrochloride

Sarafloxacin hydrochloride is a synthetic fluoroquinolone antibiotic. It is a potent inhibitor of bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. Sarafloxacin is effective against a broad spectrum of Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. It is used to treat various bacterial infections in humans and animals. Research into sarafloxacin focuses on its antimicrobial activity, pharmacokinetic properties, and potential therapeutic applications. For example, studies have investigated its effectiveness in treating respiratory tract infections, urinary tract infections, and skin infections. It is also being explored for its potential use in treating other conditions, such as tuberculosis and malaria.'

Cross-References

ID SourceID
PubMed CID56207
CHEMBL ID542157
MeSH IDM0322558

Synonyms (71)

Synonym
sarafloxacin hydrochloride
saraflox
abbott-56620
a-57135
91296-87-6
a-56620
a 56620
D05802
sarafloxacin hydrochloride (usan)
saraflox wsp (tn)
NCGC00095163-02
NCGC00095163-01
SPECTRUM1505314
sarafloxacin monohydrochloride
sarafin
nsc-758956
abbott-57135 [sarafloxacin]
sarafloxacin hcl
CHEMBL542157
HMS1922D04
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid hydrochloride
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid hydrochloride
A843795
saraflox injectable
nsc 758956
unii-i36jp4q9df
sarafloxacin hydrochloride [usan]
abbott 56620
3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, monohydrochloride
saraflox wsp
6-fluoro-1-(p-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid monohydrochloride
i36jp4q9df ,
n-methyl-1,2,3,6-tetrahydropyridine hydrochloride
nsc758956
pharmakon1600-01505314
dtxcid6025939
dtxsid8045939 ,
cas-91296-87-6
tox21_111462
AKOS016013115
CCG-39997
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
FT-0630976
S1977
sarafloxacin hydrochloride [green book]
abbott-57135 hydrochloride
sarafloxacin hydrochloride [mart.]
3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrochloride (1:1)
sarafloxacin monohydrochloride [mi]
sarafloxacin (hydrochloride)
HY-B0343A
NCGC00177995-02
tox21_111462_1
sarafloxacin hydrochloride, antibiotic for culture media use only
S-0500
S0840
a-56620 (hydrochloride)
a-56620 hcl
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride (1:1); 3-quinolinecarboxylic acid, 6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, monohydrochloride (9ci); sarafin; sarafloxacin hy
1352879-52-7
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrochloride
6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
AS-16087
BCP13147
3-quinolinecarboxylic acid,6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-,monohydrochloride
FT-0674520
mfcd03427297
Q27280302
6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid . hydrochloride
1ST5757AD8

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
TDP1 proteinHomo sapiens (human)Potency19.14800.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency21.82680.000221.22318,912.5098AID743035; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency18.99910.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.61420.000229.305416,493.5996AID743069; AID743078
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency100.00000.354828.065989.1251AID504847
lamin isoform A-delta10Homo sapiens (human)Potency2.23870.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID206539Compound was evaluated in vivo for antibacterial activity against Staphylococcus aureus NCTC 10649 (100 X LD50) (s.c. administration); Range is between (1.0-2.5)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164076Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50) (p.o. administration); Range is between (13.4-34.4)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164560In vitro antibacterial activity against Pseudomonas aeruginosa 50071986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID164561In vitro antibacterial activity against Pseudomonas aeruginosa K799/WT1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID70418In vitro antibacterial activity against Escherichia coli Juhl1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID164555In vitro antibacterial activity against Pseudomonas aeruginosa K799/WT1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164564Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50);1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID113337In vivo dose(po) inhibiting systemic infections caused by Escherichia coli Juhl in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID209294In vitro antibacterial activity against Streptococcus pyogenes 9301987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164563Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID67685In vitro antibacterial activity against Enterobacter aerogenes ATCC 130481986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID30422In vitro antibacterial activity against Acinetobacter species CMX6691986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID207963Compound was evaluated in vivo for antibacterial activity against Staphylococcus aureus NCTC 10649 (100 X LD50)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID113343In vivo dose(sc) inhibiting systemic infections caused by Escherichia coli Juhl in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID207961In vitro antibacterial activity against Staphylococcus aureus CMX 686B1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID113347In vivo dose(sc) inhibiting systemic infections caused by Staphylococcus aureus NCTC 10649 in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID115942In vivo antibacterial activity against systemic infection caused by Staphylococcus aureus NCTC 10649 in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID67684In vitro antibacterial activity against Enterobacter aerogenes ATCC 130481987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID115940In vivo antibacterial activity against systemic infection caused by Pseudomonas aeruginosa 5007 in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID113341In vivo dose(po) inhibiting systemic infections caused by Staphylococcus aureus NCTC 10649 in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID70409In vitro antibacterial activity against Escherichia coli Juhl1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID164554In vitro antibacterial activity against Pseudomonas aeruginosa 50071987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID209298In vitro antibacterial activity against Streptococcus pyogenes 9301986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID68806Compound was evaluated in vivo for antibacterial activity against Escherichia coli Juhl (100 X LD50) (s.c. administration); Range is between (0.3-1.3)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID95881In vitro antibacterial activity against Klebsiella pneumoniae 80451986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID164078Compound was evaluated in vivo for antibacterial activity against Pseudomonas aeruginosa 5007 (100 X LD50) (s.c. administration); Range is between (1.0-2.5)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID207944In vitro antibacterial activity against Staphylococcus aureus CMX 686B1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID68805Compound was evaluated in vivo for antibacterial activity against Escherichia coli Juhl (100 X LD50) (p.o. administration); Range is between (2.8-6.5)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID96096In vitro antibacterial activity against Klebsiella pneumoniae 80451987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID206215In vitro antibacterial activity against Staphylococcus epidermis 35191987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID209567In vitro antibacterial activity against Streptococcus faecium ATCC 80431987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID205588In vitro antibacterial activity against Staphylococcus epidermidis 35191986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID207943In vitro antibacterial activity against Staphylococcus aureus ATCC 6538P1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID68972Compound was evaluated in vivo for antibacterial activity against Escherichia coli Juhl (100 X LD50) (p.o. administration); Range is between (3.8-11.2)1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID115938In vivo antibacterial activity against systemic infection caused by Escherichia coli Juhl in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID30270In vitro antibacterial activity against Acinetobacter CMX 6691987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis and structure-activity relationship of 1-aryl-6,8-difluoroquinolone antibacterial agents.
AID113345In vivo dose(sc) inhibiting systemic infections caused by Pseudomonas aeruginosa 5007 in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID209569In vitro antibacterial activity against Streptococcus faecium ATCC 80431986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID113339In vivo dose(po) inhibiting systemic infections caused by Pseudomonas aeruginosa 5007 in mice.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID207960In vitro antibacterial activity against Staphylococcus aureus ATCC 6538P1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (12.50)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (50.00)24.3611
2020's6 (37.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.20 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.73 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.3720aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.3720fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
tosufloxacin
tosufloxacin: quinolone anti-infective agent; structure given in first source. tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.		1.96101,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound
difloxacin hydrochloride
[no description available]		1.9610
difloxacin
difloxacin: RN & structure given in first source. difloxacin : A quinolone that is pefloxacin in which the ethyl group at position 1 of the quinolone has been replaced by a p-fluorophenyl group. A broad-spectrum antibiotic effective against both Gram-positive and Gram-negative bacteria, it is used (usually as the monohydrochloride salt) for the treatment of bacterial infections in dogs.		1.9710fluoroquinolone antibiotic;
monocarboxylic acid;
monofluorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
Mycoplasma genitalium metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Disease
[description not available]		01.9710
Bacterial Infections
Infections by bacteria, general or unspecified.		01.9710
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Benign Neoplasms
[description not available]		03.0310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0310
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
chemdatabank.com